COMMUNIQUÉS West-GlobeNewswire

Aeroflow Health Partners with Fallon Health to Expand DME Access to Commercial and Medicare Members in Massachusetts
01/09/2026
Commercial and Medicare members under Fallon Health gain easy access to critical care supplies such as breast pumps and CPAPs. ASHEVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health , a technology-enabled [...]
Patients Suffering from Primary Biliary Cholangitis (PBC) Push Back on Stigma
01/09/2026
National Voice of PBC Survey Unveils the Significant Physical, Emotional and Social Impact of PBC ROCHESTER, N.Y., Sept. 01, 2026 (GLOBE NEWSWIRE) -- This September, in recognition of PBC Awareness Month, The PBCers [...]
Olympia Pharmaceuticals Adds Gonadorelin to Its Growing Men’s Hormone Portfolio
01/09/2026
A synthetic copy of the hormone signal that prompts the body to make testosterone, the new 1 mg/mL formulation is now available to providers in 49 states for office use ORLANDO, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- [...]
Editas Medicine to Participate in Upcoming Investor Conferences
01/09/2026
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]
Solera Health Adds Noom to Its Weight Management Network, Expanding Digital-First Options for Members
01/09/2026
Partnership brings CDC Full Plus-recognized diabetes prevention program and a no-cost GLP-1 Companion offering to Solera's curated network, in addition to its Noom Weight offering PHOENIX, Sept. 01, 2026 (GLOBE NEWSWIRE [...]
Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive Head and Neck Cancer
01/09/2026
BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole, [...]
BiomX Inc. to Become Tessera Defense and Homeland Security Inc.
01/09/2026
Name change effective September 11, 2026; common stock to trade on the NYSE American under the new symbol “HLSQ” NETANYA, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today [...]
Inner Voyage Recovery Center earns The Joint Commission's Gold Seal of Approval following unannounced survey
01/09/2026
Woodstock outpatient program maintains national accreditation for behavioral health care after three-year review cycle Woodstock, GA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Inner Voyage Recovery Center, an outpatient [...]
New York Plastic Surgical Group Welcomes Two New Surgeons to Its Team
01/09/2026
Garden City, NY, Sept. 01, 2026 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group), one of the nation's most respected plastic surgery practices, proudly welcomes two new surgeons, Steven Cai, MD , and Ian [...]
Attelia Expands the International Patient Experience with New Health Tour Mobile App
01/09/2026
The personalised platform brings treatment planning, online consultations, appointments, transfers, real-time support and long-term aftercare into one secure digital journey ANTALYA, Turkiye, Sept. 01, 2026 (GLOBE [...]
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
01/09/2026
Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that [...]
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
01/09/2026
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The [...]
Harrow to Participate in Three Investor Conferences in September
01/09/2026
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the [...]
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
01/09/2026
Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and Abivax TORONTO, Sept. 01, 2026 ( [...]
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
01/09/2026
MILAN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) with clinical programs in Usher syndrome type 1B [...]
Syndax Announces Participation in September Investor Conferences
01/09/2026
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Remix Therapeutics to Participate in Upcoming Investor Conferences
01/09/2026
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying [...]
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
01/09/2026
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by [...]
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
01/09/2026
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]

Pages